http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2001504435-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K41-0071 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K41-0066 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D493-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-407 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-409 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4375 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D519-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D493-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K41-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-366 |
| filingDate | 1996-07-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2001-04-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2001504435-A |
| titleOfInvention | Photoactive compounds that inhibit intimal hyperplasia and other diseases |
| abstract | (57) [Summary] In photosensitization therapy, a broad class of photosensitizers with strong selectivity and diversity for target tissues in vivo. Many flocoumarin compounds, such as psoralens, exhibit cytostatic activity when photoactivated, but show little in vivo specificity for selective accumulation in specific target tissues, such as atherosclerotic plaques. Reactive oxygen producing photosensitizers ("ROPPs") are photosensitizers that have an affinity for hyperproliferating cells (such as atherosclerotic plaque cells). The photoactivity of ROPPs such as porphyrins may be reduced by metallation of porphyrins, but the selective affinity of metalated ROPPs for hyperproliferative tissue remains essentially unchanged. When a flocoumarin compound is bound to ROPP to form F-ROPP, the cytostatic properties of the flocoumarin portion of F-ROPP can be exploited, while ROPP of the compound against hyperproliferating cells such as atherosclerotic plaques The selective affinity of the moieties provides strong tissue selectivity without cytotoxicity. In vivo, certain F-ROPPs selectively accumulate in the target tissue by irradiating the target tissue with light of a wavelength that can photoactivate the F portion of the F-ROPP, thereby causing F-ROPP to accumulate in the target tissue. Monoadducts can be formed or crosslinked with cellular DNA. Thereafter, light of the second wavelength is delivered to the target tissue, which can photoactivate the ROPP moiety to further inhibit cell activity. |
| priorityDate | 1995-07-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 102.